Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Big Is The Scleroderma Market Today And What Is Its Future Size?
The market size for scleroderma has seen significant expansion in recent periods. It is projected to rise from $2.33 billion in 2024 to $2.48 billion in 2025, with a compound annual growth rate (CAGR) of 6.6%. The growth witnessed in the historical period is credited to developments in diagnosis, research in immunology, therapeutic advancements, increased awareness and education, as well as genetic studies.
The market size for scleroderma is predicted to witness robust expansion in the upcoming years. The growth will escalate to $3.24 billion in 2029, with a compound annual growth rate (CAGR) of 6.9%. The anticipated growth within the specified period can be credited to advancements in biological therapies, precision medicine, stem cell therapies, along with genomic and biomarker research and international collaborations. Notable trends during this forecast period will be the rising preference for digital health solutions, an emphasis on microbiome, patient-oriented care, regenerative medicine, as well as health equality and accessibility.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12615&type=smp
What External And Internal Drivers Are Influencing The Scleroderma Market?
The escalating instances of scleroderma are impelling the progression of the scleroderma market. Characterized as a long-term autoimmune disorder, scleroderma involves the unusual proliferation of collagen — a protein constituting the structure of skin and various tissues. This condition is developed due to an uncontrolled immune response likely activated by different environmental aspects. As the frequency of the disease increases, the significance of better diagnosis and treatment becomes conspicuous. The potential role of scleroderma therapeutics becomes notable for controlling the disease and reducing symptoms by modulating the immune reaction and lessening the vulnerability to environmental danger factors. For example, as reported by Karger Publishers, a Switzerland-origin publisher of meticulously reviewed journals, in June 2022, 19,000 people in the UK and 2.5 million people globally were scleroderma patients. Furthermore, an academic write-up put forth by the Oxford Academic Press, a university press affiliated with the University of Oxford in the UK, acknowledged the identification of 1,588 systemic sclerosis (SSc) cases from a population of 10.1 million individuals in the CPRD in August 2024. These cases further led to the identification of 206 cancers, predominantly mucocutaneous (4.5%), lung (2.1%), and breast (1.9%). Hence, the increased occurrence of scleroderma is propelling the scleroderma market.
How Is The Scleroderma Market Categorized Across Applications And Types?
The sclerodermamarket covered in this report is segmented –
1) By Treatment: Medication; Surgery; Other Treatments
2) By Indication: Systemic Scleroderma; Localized Scleroderma
3) By End User: Hospital; Pharmaceutical Stores; Other End Users
Subsegments:
1) By Medication: Immunosuppressants; Antifibrotic Agents; Vasodilators; Corticosteroids; Pain Relievers
2) By Surgery: Lung Transplantation; Other Surgical Interventions
3) By Other Treatments: Physical Therapy; Occupational Therapy; Lifestyle Modifications; Alternative Therapies
How Are Market Trends Influencing Competition In The Scleroderma Market?
The trend of creating innovative treatments is rising in prominence in the scleroderma market. Primary players in this sector are in the process of formulating unique medications to handle the symptoms and maintain their industry standing. For instance, Tyr Pharma Inc., a biopharmaceutical firm based in the US, was granted sanction for its pioneering systemic sclerosis-related interstitial lung disease medication, efzofitimod, by the US Food and Drug Administration, a US health regulatory authority, in April 2022. This first-of-its-kind immunomodulator is designed to regulate the immune response by adjusting the neuropilin-2 (NRP2) receptor, thereby minimizing scleroderma symptoms. Efzofitimod also aims at the same immune cells that cause the pathology of SSc-ILD (interstitial lung disease associated with systemic sclerosis) and pulmonary sarcoidosis. This led to a decrease in pro-inflammatory markers in a clinical trial involving patients afflicted with pulmonary sarcoidosis.
Who Are The Global Leaders Steering The Scleroderma Market Forward?
Major companies operating in the scleroderma market include Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, Abbvie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., GSK plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim International GmbH, Principia Biopharma Corp, aTyr Pharma Inc., Cumberland Pharmaceuticals Inc., Kadmon Holdings Inc., Emerald Health Pharmaceuticals Inc., FibroGen Inc., Argentis Pharmaceuticals LLC, Corbus Pharmaceuticals Holdings Inc., H.A.C. Pharma
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report
What Are The Emerging Regional Trends Driving The Scleroderma Market?
North America was the largest region in the scleroderma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=12615&type=smp
Browse Through More Reports Similar to the Global Scleroderma Market 2025, By The Business Research Company
Autoimmune Treatment Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/autoimmune-treatment-global-market-report
Dermatitis Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report
Dermatology Medical Lasers Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/dermatology-medical-lasers-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model